Loading company…
oligoNgene develops gene and cell therapies for hereditary retinal diseases.
Founded in 2023, oligoNgene researches gene and cell therapies for hereditary retinal diseases, using adeno-associated virus vectors and human iPS cell-derived retinal organoids. The company is based in Gyeonggi-do, South Korea, and led by founder and representative director Park Tae-gwan. In August 2023, it raised seed funding led by Genaxis.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in